Safety and Efficacy of Iron Chelators in Patients With Chronic Kidney Disease: A Systematic Review and Meta-Analysis.
Humam Emad Rajha, Richard Shamoon, Ameer Almeshagbeh et al.
✦ AI-curated · Sources linked
In 30 seconds
This systematic review and meta-analysis evaluated the efficacy and safety of iron chelators in adults with chronic kidney disease, analyzing data from 11 studies involving 206 patients. Iron chelation significantly reduced serum ferritin, transferrin, and serum iron levels, while hemoglobin increased by 1.07 g/dL. The findings suggest potential benefits in managing iron overload and anemia in this population.
Key findings
- Iron chelation reduced serum ferritin by 1.48 μg/L.
- Transferrin levels decreased by 10.6 mg/dL.
- Serum iron levels decreased by 24.2 μg/dL.
- Hemoglobin increased by 1.07 g/dL.
Why it matters
Understanding the role of iron chelators in chronic kidney disease is crucial, as iron overload can exacerbate oxidative injury and anemia. This study provides insights into potential therapeutic benefits, although further research is needed.
What to keep in mind
The evidence was limited by high heterogeneity and potential bias, with small sample sizes across studies.